New Drugs for Resistant Hypertension: Pending Issue?

Antihypertensive pharmacological treatment, based on currently available drugs, has been shown to reduce the cardiovascular risk profile of treated hypertensive patients by lowering elevated blood pressure. However, the cardiovascular risk in treated hypertensive patients remains elevated. This highlights the need to develop new antihypertensive drugs capable of normalizing the risk associated with high blood pressure. This paper aims to review new antihypertensive drugs for the treatment of drug-resistant hypertension. In particular, it focuses on the results obtained with non-steroidal mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, brain renin-angiotensin blockers, hepatic angiotensinogen inhibitors, atrial natriuretic peptides, and endothelin-1 receptors antagonists.